Literature DB >> 7674469

Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine.

M C Mauney1, S A Buchanan, W A Lawrence, A Bishop, K Sinclair, T M Daniel, C G Tribble, I L Kron.   

Abstract

PURPOSE: Postoperative neurologic injury remains a significant risk of carotid endarterectomy. Mechanisms include embolization of debris and formation of thrombus on the newly endarterectomized surface. We hypothesized that the risk of postoperative neurologic injury would be lower in those patients who did not receive protamine for reversal of heparin anticoagulation.
METHODS: We reviewed 348 consecutive primary carotid endarterectomies performed since January 1, 1986, to determine the relationship between surgical outcomes and reversal of heparin anticoagulation. Patients undergoing additional simultaneous cardiovascular procedures were excluded. One hundred ninety-three patients received protamine after completion of the endarterectomy. The remaining 155 patients did not receive any protamine.
RESULTS: All patients in both groups survived to discharge. There were no strokes in those patients who did not receive any protamine; however, the stroke rate in the protamine group was 2.6% (5 of 193), p < 0.045. The incidence of hematoma requiring reexploration was 1.0% (2 of 193) and 1.9% (3 of 155) in the protamine and no-protamine groups, respectively (p = NS). Intraoperative shunting was used more frequently in the no-protamine group (84% vs 67%, p < 0.001), and patch angioplasty was performed more frequently in the protamine group (35% vs 15%, p < 0.001). However, neither shunting nor patching significantly influenced stroke rates.
CONCLUSIONS: We conclude that carotid endarterectomy without reversal of heparin anticoagulation is associated with a reduced postoperative stroke rate without a significant increase in morbidity rates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7674469     DOI: 10.1016/s0741-5214(95)70140-0

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  Shared quality data are associated with increased protamine use and reduced bleeding complications after carotid endarterectomy in the Vascular Study Group of New England.

Authors:  Reshma B Patel; Peter Beaulieu; Karen Homa; Philip P Goodney; Andrew C Stanley; Jack L Cronenwett; David H Stone; Daniel J Bertges
Journal:  J Vasc Surg       Date:  2013-09-05       Impact factor: 4.268

2.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

3.  Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke.

Authors:  David H Stone; Brian W Nolan; Andres Schanzer; Philip P Goodney; Robert A Cambria; Donald S Likosky; Daniel B Walsh; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2010-01-04       Impact factor: 4.268

4.  Using protamine can significantly reduce the incidence of bleeding complications after carotid endarterectomy without increasing the risk of ischemic cerebral events.

Authors:  Franco Mazzalai; Giacomo Piatto; Antonio Toniato; Renata Lorenzetti; Claudio Baracchini; Enzo Ballotta
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

5.  Emergency reversal of antithrombotic treatment.

Authors:  Marcel Levi
Journal:  Intern Emerg Med       Date:  2008-11-12       Impact factor: 3.397

Review 6.  A Meta-Analysis of Using Protamine for Reducing the Risk of Hemorrhage During Carotid Recanalization: Direct Comparisons of Post-operative Complications.

Authors:  Yongli Pan; Zhiqiang Zhao; Tao Yang; Qingzheng Jiao; Wei Wei; Jianyong Ji; Wenqiang Xin
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.